News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kineta Inc. Programs Named "Top Projects" Second Year Running


11/30/2011 9:02:31 AM

SEATTLE--(BUSINESS WIRE)--Kineta’s two lead drug development programs will be honored by the pharmaceutical industry this week for their scientific distinction and likelihood to rapidly progress to high-value partnering deals. Both ShK-186 and r-OAS1, Kineta’s autoimmune and antiviral programs, were named among the “Top Projects to Watch” by Windhover and Elsevier Business Intelligence companies.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES